- DIA is a professional community and knowledge exchange network for global health care product development
- Mr. Roberts, who is also the Chief Operating Officer and EVP of Finance at Cancer Genetics, Inc. (Nasdaq:CGIX) will serve a one year term in the role through 2018
RUTHERFORD, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that DIA (founded as the Drug Information Association), a global, nonprofit, membership association dedicated to bringing health care product development professionals together in a trusted, transparent, neutral environment, has elected John A. (Jay) Roberts as Chairman of the Board of Directors for the one-year term of 2017 – 2018.
Currently, Mr. Roberts is the Chief Operating Officer and Executive Vice President of Finance for CGI. With a global footprint, CGI is a leader in the discovery, development and commercialization of unique genomic and biomarker tests that accelerate drug development and clinical trials, while also enabling precision oncology in the clinical setting.
Mr. Roberts was first elected to the DIA Board of Directors in July 2009, assuming the role of Chairman of the Audit Committee. He has since served as the DIA Chairman of the Finance Committee, Treasurer, and a member of the Executive Committee since 2013. Prior to his current engagements, Mr. Roberts has held a number of senior executive positions for global publicly-traded and private equity-backed health care information technology, software development and services firms over a 30-year professional career.
“We are extremely pleased to welcome Jay as the new Chairman of the Board of Directors for DIA. As a recognized thought leader, his experience and expertise will help to strengthen and expand DIA’s global voice, helping to ensure we remain on the forefront of the life sciences ecosystem providing our members and all stakeholders with key insights to succeed in the rapidly evolving health care arena,” said Barbara Lopez Kunz, Global Chief Executive, DIA.
Founded in 1964, DIA (the Drug Information Association) is a global, nonprofit, membership association dedicated to bringing health care product development professionals together in a trusted, transparent, neutral environment.. Advancing through thought leadership, DIA provides international professionals a neutral and transparent forum for the exchange of ideas and collaboration to improve health globally through the advancement of lifesaving medicines and technologies. DIA offers knowledge resources and forums on product development, regulatory science, and therapeutic innovation for professionals in the pharmaceutical, biotechnology, and medical device communities.
DIA is based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, Africa and the Middle East (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and, Tokyo, Japan).
ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Investor Relations Contact: Richard Moyer Cameron Associates 535 Fifth Ave., New York, NY 10017 Tel: 212-554-5466 Email: email@example.com